Vertex Pharma (VRTX): VX-661/Kalydeco Combo Fails But Was A Long Shot - Baird

August 16, 2016 8:34 AM EDT
Get Alerts VRTX Hot Sheet
Price: $80.68 +2.50%

Rating Summary:
    27 Buy, 14 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 26 | New: 7
Trade VRTX Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Vertex (NASDAQ: VRTX) as the company followed in Orkambi's footsteps when the VX-661/ivacaftor failed to show a benefit in patients heterozygous for the F508del mutation and a mutation resulting in minimal CFTR function (F508del het/mins).

The analyst had been skeptical from the start, but the next-gen triple combos are expected to move into Phase 2 soon. This is an effort the analyst is far more enthusiastic about for this subgroup of CF patients.

No change to the price target of $128.

For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.

Shares of Vertex closed at $102.48 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Robert W Baird

Add Your Comment